Positron Emission Tomography in Bone and Soft Tissue Tumors

  • Sofia N. ChatziioannouEmail author
  • Nikoletta K. Pianou


Positron emission tomography/computed tomography with the use of 18F-fluorodeoxyglucose (18F-FDG PET/CT) is an imaging modality that combines both functional and anatomical information. The combination of PET with CT has been established as an imaging modality and is currently widely used in oncology. Bone and soft tissue tumors, as of course the majority of tumors, are characterized of multiple metabolic and molecular alterations, which allow imaging with positron emitters. These alterations include increased glucolysis, increased amino acid, and increased nucleic acid metabolic activity.


  1. 1.
    Schwarzbach MHM, Hinz U, Dimitrakopoulou-Strauss A et al (2005) Prognostic significance of preoperative (18-F)fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg 241:286–294CrossRefGoogle Scholar
  2. 2.
    Fuglø HM, Jørgensen SM, Loft A et al (2012) The diagnostic and prognostic value of 18F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients. Eur J Nucl Med Mol Imaging 39:1416–1424CrossRefGoogle Scholar
  3. 3.
    Tateishi U, Yamaguchi U, Seki K et al (2007) Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology 245(3):839–847CrossRefGoogle Scholar
  4. 4.
    Franzius C, Sciuk J, Daldrup-Link HE et al (2000) FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 27:1305–1311CrossRefGoogle Scholar
  5. 5.
    Völker T, Denecke T, Steffen I et al (2007) Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 25:5435–5441CrossRefGoogle Scholar
  6. 6.
    Franzius C, Daldrup-Link HE, Sciuk J et al (2001) FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 12:479–486CrossRefGoogle Scholar
  7. 7.
    Herrmann K, Benz M, Czernin J et al (2012) 18F-FDG-PET/CT imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clin Cancer Res 18:2024–2031CrossRefGoogle Scholar
  8. 8.
    Fendler WP, Lehmann M, Todica A et al (2015) PET response criteria in solid tumors predicts progression-free survival and time to local or distant progression after chemotherapy with regional hyperthermia for soft-tissue-sarcoma. J Nucl Med 56:530–537CrossRefGoogle Scholar
  9. 9.
    Koshkin V, Bolejack V, Schwartz L et al (2016) Assessment of imaging modalities and response metrics in Ewing sarcoma: correlation with survival. J Clin Oncol 34:3680–3685CrossRefGoogle Scholar
  10. 10.
    Treglia G, Mirk P, Stefanelli A et al (2012) 18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: a systematic review. Clin Imaging 36:167–175CrossRefGoogle Scholar
  11. 11.
    Holdsworth CH, Badawi RD, Manola JB et al (2007) CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol 189:W324–W330CrossRefGoogle Scholar
  12. 12.
    Demetri GD, Heinrich MC, Fletcher JA et al (2009) Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 15:5902–5909CrossRefGoogle Scholar
  13. 13.
    Fuster D, Ayuso JR, Poveda A et al (2011) Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study. Q J Nucl Med Mol Imaging 55:680–687PubMedGoogle Scholar
  14. 14.
    Fendler WP, Chalkidis RP, Ilhan H et al (2015) Evaluation of several FDG parameters for prediction of soft tissue tumor grade at primary diagnosis and recurrence. Eur Radiol 25:2214–2221CrossRefGoogle Scholar
  15. 15.
    Miyake KK, Nakamoto Y, Mikami Y et al (2016) The predictive value of preoperative 18F-fluorodeoxyglucose PET for postoperative recurrence in patients with localized primary gastrointestinal stromal tumor. Eur Radiol 26:4664–4674CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Sofia N. Chatziioannou
    • 1
    • 2
    Email author
  • Nikoletta K. Pianou
    • 3
  1. 1.2nd Department of Radiology, Nuclear Medicine SectionNational and Kapodistrian University of Athens, “Attikon” University General HospitalAthensGreece
  2. 2.Nuclear Medicine Division, PET/CT DepartmentBiomedical Research Foundation, Academy of AthensAthensGreece
  3. 3.Nuclear Medicine Division, PET/CT DepartmentBiomedical Research Foundation, Academy of AthensAthensGreece

Personalised recommendations